Advertisement
Screener

ADC Therapeutics SA (ADCT) Adjustments For Amortisation Expense

2.8 / 5 stars · 68/120 Roast Me

ADC Therapeutics SA Adjustments For Amortisation Expense

ADC Therapeutics SA (ADCT) reported Adjustments For Amortisation Expense of $155.00 thousand for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.

Discontinued › Expense Statement › Operating Expenses

ifrs-full:AdjustmentsForAmortisationExpense · last filed 2023-11-07

  • ADC Therapeutics SA adjustments for amortisation expense for the quarter ending 2023-09-30 was $52.00K, a 67.74% increase year-over-year.
  • ADC Therapeutics SA adjustments for amortisation expense for the quarter ending 2023-06-30 was $51.00K, a 64.52% increase year-over-year.
  • ADC Therapeutics SA adjustments for amortisation expense for the quarter ending 2023-03-31 was $52.00K, a 100.00% increase year-over-year.
  • ADC Therapeutics SA adjustments for amortisation expense for the quarter ending 2022-12-31 was $30.00K, a 9.09% decline year-over-year.
Period endAdjustments For Amortisation Expense 3 monthAdjustments For Amortisation Expense 6 monthAdjustments For Amortisation Expense 9 monthAdjustments For Amortisation Expense 12 month
2023-09-30$52.00K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07
$103.00K
derived: sum of 2 quarters · filed 2023-11-07
$155.00K
6-K · filed 2023-11-07
$185.00K
derived: sum of 4 quarters · filed 2023-11-07
2023-06-30$51.00K
derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08
$103.00K
6-K · filed 2023-08-08
$133.00K
derived: sum of 3 quarters · filed 2023-08-08
$164.00K
derived: sum of 4 quarters · filed 2023-11-07
2023-03-31$52.00K
6-K · filed 2023-05-09
$82.00K
derived: sum of 2 quarters · filed 2023-05-09
$113.00K
derived: sum of 3 quarters · filed 2023-11-07
$144.00K
derived: sum of 4 quarters · filed 2023-11-07
2022-12-31$30.00K
derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15
$61.00K
derived: sum of 2 quarters · filed 2023-11-07
$92.00K
derived: sum of 3 quarters · filed 2023-11-07
$118.00K
20-F · filed 2023-03-15
2022-09-30$31.00K
derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07
$62.00K
derived: sum of 2 quarters · filed 2023-11-07
$88.00K
6-K · filed 2023-11-07
$121.00K
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30$31.00K
derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08
$57.00K
6-K · filed 2023-08-08
$90.00K
derived: sum of 3 quarters · filed 2023-08-08
$123.00K
derived: sum of 4 quarters · filed 2023-08-08
2022-03-31$26.00K
6-K · filed 2023-05-09
$59.00K
derived: sum of 2 quarters · filed 2023-05-09
$92.00K
derived: sum of 3 quarters · filed 2023-05-09
$130.00K
derived: sum of 4 quarters · filed 2023-05-09
2021-12-31$33.00K
derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15
$66.00K
derived: sum of 2 quarters · filed 2023-03-15
$104.00K
derived: sum of 3 quarters · filed 2023-03-15
$129.00K
20-F · filed 2023-03-15
2021-09-30$33.00K
derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08
$71.00K
derived: sum of 2 quarters · filed 2022-11-08
$96.00K
6-K · filed 2022-11-08
$115.00K
derived: sum of 4 quarters · filed 2023-03-15
2021-06-30$38.00K
derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09
$63.00K
6-K · filed 2022-08-09
$82.00K
derived: sum of 3 quarters · filed 2023-03-15
$93.00K
derived: sum of 4 quarters · filed 2023-03-15
2021-03-31$25.00K
6-K · filed 2022-05-09
$44.00K
derived: sum of 2 quarters · filed 2023-03-15
$55.00K
derived: sum of 3 quarters · filed 2023-03-15
$63.00K
derived: sum of 4 quarters · filed 2023-03-15
2020-12-31$19.00K
derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15
$30.00K
derived: sum of 2 quarters · filed 2023-03-15
$38.00K
derived: sum of 3 quarters · filed 2023-03-15
$47.00K
20-F · filed 2023-03-15
2020-09-30$11.00K
derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02
$19.00K
derived: sum of 2 quarters · filed 2021-11-02
$28.00K
6-K · filed 2021-11-02
2020-06-30$8.00K
derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03
$17.00K
6-K · filed 2021-08-03
2020-03-31$9.00K
6-K · filed 2021-05-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
LIFECORE BIOMEDICAL, INC. DE (LFCR)United States$0.163B-8.50
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Annexon, Inc. (ANNX)United States$0.147B-4.22
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Corbus Pharmaceuticals Holdings, Inc. (CRBP)United States$0.144B-1.72
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
SPRUCE BIOSCIENCES, INC. (SPRB)United States$0.142B-2.89
Korro Bio, Inc. (KRRO)United States$0.141B-1.81
PepGen Inc. (PEPG)United States$0.186B-1.73